Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M78,658Revenue (TTM) $M24,766Net Margin (%)11.8Altman Z-Score1.7
Enterprise Value $M88,228EPS (TTM) $1.2Operating Margin %17.0Piotroski F-Score7
P/E(ttm)30.3Beneish M-Score-2.6Pre-tax Margin (%)12.6Higher ROA y-yY
Price/Book5.610-y EBITDA Growth Rate %-0.2Quick Ratio0.7Cash flow > EarningsY
Price/Sales3.55-y EBITDA Growth Rate %-17.9Current Ratio0.8Lower Leverage y-yN
Price/Free Cash Flow34.0y-y EBITDA Growth Rate %25.6ROA % (ttm)5.1Higher Current Ratio y-yN
Dividend Yield %4.5PEG--ROE % (ttm)17.0Less Shares Outstanding y-yY
Payout Ratio %122Shares Outstanding M2,530ROIC % (ttm)15.6Gross Margin Increase y-yY

Gurus Latest Trades with AZN

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
AZNDodge & Cox 2016-03-31 Add0.39%$27.95 - $33.95
($30.11)
$ 31.133%Add 121.19%26,049,650
AZNNWQ Managers 2016-03-31 Reduce$27.95 - $33.95
($30.11)
$ 31.133%Reduce -1.83%506,785
AZNKen Fisher 2016-03-31 Add$27.95 - $33.95
($30.11)
$ 31.133%Add 5.33%233,409
AZNDodge & Cox 2015-12-31 Buy 0.39%$30.47 - $34.77
($32.84)
$ 31.13-5%New holding11,777,132
AZNKen Fisher 2015-12-31 Add0.01%$30.47 - $34.77
($32.8)
$ 31.13-5%Add 692.95%221,606
AZNNWQ Managers 2015-12-31 Add0.01%$30.47 - $34.77
($32.84)
$ 31.13-5%Add 5.24%516,215
AZNNWQ Managers 2015-09-30 Add0.09%$30.28 - $34.54
($32.89)
$ 31.13-5%Add 60.04%490,535
AZNMario Gabelli 2015-09-30 Sold Out $30.28 - $34.54
($32.89)
$ 31.13-5%Sold Out0
AZNKen Fisher 2015-09-30 Buy $30.28 - $34.54
($32.89)
$ 31.13-5%New holding27,947
AZNDavid Dreman 2015-06-30 Sold Out -0.16%$31.86 - $36.68
($34.25)
$ 31.13-9%Sold Out0
AZNNWQ Managers 2015-06-30 Add0.12%$31.86 - $36.68
($34.25)
$ 31.13-9%Add 486.45%306,510
AZNMario Gabelli 2015-06-30 Reduce$31.86 - $36.68
($34.25)
$ 31.13-9%Reduce -28.81%8,400
AZNDavid Dreman 2015-03-31 Reduce-0.01%$32.22 - $36.35
($34.77)
$ 31.13-10%Reduce -4.43%54,978
AZNNWQ Managers 2015-03-31 Reduce-0.01%$32.22 - $36.35
($34.77)
$ 31.13-10%Reduce -21.34%104,530
AZNMario Gabelli 2015-03-31 Reduce$32.22 - $36.35
($34.77)
$ 31.13-10%Reduce -40.70%23,600
AZNDavid Dreman 2014-12-31 Reduce-0.51%$33.58 - $37.69
($35.82)
$ 31.13-13%Reduce -75.42%57,528
AZNGeorge Soros 2014-12-31 Sold Out -0.08%$33.58 - $37.69
($35.82)
$ 31.13-13%Sold Out0
AZNMario Gabelli 2014-12-31 Reduce-0.01%$33.58 - $37.69
($35.82)
$ 31.13-13%Reduce -52.51%39,800
AZNNWQ Managers 2014-12-31 Add$33.58 - $37.69
($35.82)
$ 31.13-13%Add 3.05%132,880
AZNCharles Brandes 2014-09-30 Sold Out -0.35%$34.25 - $38.16
($36.64)
$ 31.13-15%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

AZN is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


AZN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
ASTRAZENECA PLC10% Owner 2014-11-12Sell2,000,000$1783.12view

Quarterly/Annual Reports about AZN:

    News about AZN:

    Articles On GuruFocus.com
    Dividend and Value Opportunities in the Large-Cap Pharmaceutical Space Apr 05 2016 
    Francis Chou Raises Stake in Resolute Forest Products Mar 20 2016 
    Signature Select Canadian Fund Second Quarter 2015 Market Commentary Sep 22 2015 
    Francis Chou Doubles Stake in AstraZeneca Aug 11 2015 
    Last Month Insiders Bought Over $300 Million Of This Biotech Jun 26 2015 
    Guru Stocks at 52-Week Lows: XOM, WMT, CVX, AZN, COP Jun 21 2015 
    Amgen And AstraZeneca’s Deal On Psoriasis Drug Faces Termination May 27 2015 
    Johnson & Johnson A Good Investment Despite Current Lows May 14 2015 
    Vanguard Adds to Four of Its Largest Stakes May 04 2015 
    HealthCare Stocks That Can Make Investors Healthier Apr 08 2015 

    More From Other Websites
    [$$] New drugs aim to kill cancer cells by destabilising their DNA Jul 24 2016
    Corporate raiders seek Brexit bargains in Britain Jul 24 2016
    3 post-Brexit picks I’d buy now Jul 22 2016
    Relypsa Getting Acquired By Swiss Partner Seeking U.S. Entry Jul 21 2016
    Here’s what Neil Woodford has been buying and selling since the Brexit vote Jul 21 2016
    Your inhaler's watching you: drugmakers race for smart devices Jul 20 2016
    Your inhaler's watching you: drugmakers race for smart devices Jul 20 2016
    Your inhaler's watching you: drugmakers race for smart devices Jul 20 2016
    Indian Firms Get Approval for Generics of AstraZeneca Drug Jul 20 2016
    Judge refuses to block generic versions of AstraZeneca's Crestor Jul 19 2016
    Judge refuses to block generic versions of AstraZeneca's Crestor Jul 19 2016
    Judge refuses to block generic versions of AstraZeneca's Crestor Jul 19 2016
    AstraZeneca's (AZN) Tagrisso Hits Phase III Primary Endpoint Jul 19 2016
    AstraZeneca Fails to Keep Generic Crestor Rivals Off Market Jul 19 2016
    FDA Advisory Committee Recommends Approval Of Brodalumab For Treatment Of Moderate-To-Severe Plaque... Jul 19 2016
    FDA Advisory Committee Recommends Approval Of Brodalumab For Treatment Of Moderate-To-Severe Plaque... Jul 19 2016
    U.S. FDA panel backs Valeant psoriasis drug with risk program Jul 19 2016
    Will GlaxoSmithKline plc and AstraZeneca plc continue to be Brexit winners? Jul 19 2016
    SoftBank to buy UK chip designer ARM in $32 bln cash deal Jul 18 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)